Alisha Maher

Medicine & Life Sciences

1. Randomized Controlled Trials 100%
2. Labetalol 68%
3. dilapan 58%
4. Induced Labor 58%
5. Continuous Positive Airway Pressure 56%
6. Nifedipine 51%
7. Mothers 49%
8. Obstructive Sleep Apnea 48%
9. Dinoprostone 46%
10. Pregnancy 35%
11. Type 2 Diabetes Mellitus 35%
12. Hypertension 30%
13. Hemorrhage 30%
14. Random Allocation 23%
15. Antihypertensive Agents 21%
16. Therapeutics 17%
17. Cost-Benefit Analysis 15%
18. Fibrosis 11%
19. Sample Size 9%
20. Costs and Cost Analysis 9%
21. Pregnancy Induced Hypertension 9%
22. Shared Decision Making 9%
23. Quality of Life 9%
24. Fetal Death 9%
25. Perinatal Death 9%
26. Publications 8%
27. Chronic Renal Insufficiency 8%
28. Cervical Ripening 8%
29. Calcium Channel Blockers 8%
30. Endoscopic Hemostasis 7%
31. Pre-Eclampsia 7%
32. Uncertainty 7%
33. Health Care Outcome Assessment 6%
34. Intention to Treat Analysis 6%
35. Gestational Age 6%
36. Transplants 6%
37. Risk Assessment 6%
38. Maternal Age 6%
39. Pandemics 6%
40. End Stage Liver Disease 6%
41. Parity 6%
42. Cervix Uteri 5%
43. Survival 5%
44. Telephone 5%
45. Research Ethics Committees 5%
46. National Health Programs 5%
47. Ethics 5%
48. Sleep Wake Disorders 5%
49. Exercise 5%
50. Guidelines 5%